P2.04 NGS-Molecular Characterization of Lung Adenocarcinomas from Hispanic Patients: Level of Evidence for Therapeutic Actionability

Abstract

, 748 patients with a diagnosis of advanced NSCLC and CEA levels >20 ng/mL were included in the analysis. The median age was 60.2 years old, 631 patients (84.4%) had adenocarcinoma histology. From 338 patients evaluated for EGFR mutations, 139 (31.3%) harboured an EGFR mutation. The median OS was 23.3 months (95% CI 19.4-26.9) in patients who completely normalized CEA vs 10.0 months (95% CI 8.9-11.2) in patients who did not achieve CEA normalization, with an HR 0.48 95% CI (0.35-0.67) p <0.0001. The median OS was 15.5 months (95% CI 13.4-17.6) in patients who showed a decrease in CEA levels vs 8.8 months (95% CI 7.5-10.1) in those who did not. Reduction in CEA levels was associated with better OS, either in patients treated with TKI or platinum-based chemotherapy. Conclusion: Although previous studies have suggested a possible relation between CEA levels and clinical outcome, its utility in the clinic has been controversial. In this study, we demonstrate normalization of serum CEA levels is related to longer OS rates and could be useful as an indirect biomarker for treatment response evaluation. Hence, we suggest its determination for the standard follow-up of advanced NSCLC patients under TKI or platinum-based chemotherapy treatment.